Table 1 The demographics of clinical factors for patients in the training and validation sets
|  | Training Set (N = 216) | Validation Set (N = 93) | p-value | ||
|---|---|---|---|---|---|
|  | MVI+ (N = 68) | MVI- (N = 148) | MVI+ (N = 28) | MVI- (N = 65) | 0.41 |
Median of age in years (Q.25-Q.75) | 58 (53–68) | 60 (50–68.3) | 65 (58.3–72.5) | 59 (54–67) | 0.32 |
Gender | 0.12 | ||||
 Male | 55 (80.9%) | 103 (69.6%) | 21 (75%) | 53 (81.5%) |  |
 Female | 13 (19.1%) | 45 (30.4%) | 7 (25%) | 12 (18.5%) |  |
 Median of MTD in mm (Q.25-Q.75) | 4.5 (3–7.4) | 2.2 (1.5–3.4) | 5.9 (3.9–6.9) | 2.5 (2–4.2) | 0.12 |
 Median of AFP in ng/ml (Q.25-Q.75) | 33.5 (6.5–1294.9) | 11.4 (3.7–209.6) | 9.2 (3.8–328.1) | 7 (3.13–71.85) | 0.87 |
Child-Pugh score | 0.12 | ||||
 A | 64 (94.1%) | 139 (93.9%) | 25 (89.3%) | 59 (90.6%) |  |
 B | 4 (5.8%) | 7 (4.7%) | 2 (7.1%) | 4 (6.2%) |  |
 C | 0 (0%) | 2 (1.4%) | 1 (3.6%) | 2 (3.1%) |  |
HBsAg | 0.22 | ||||
 Positive | 37 (54.4%) | 78 (52.7%) | 11 (39.3%) | 43 (66.2%) |  |
 Negative | 31 (45.6%) | 70 (47.3%) | 17 (60.7%) | 22 (33.8%) |  |
HCsAg | 0.27 | ||||
 Positive | 23 (33.8%) | 52 (35.1%) | 11 (39.3%) | 18 (27.7%) |  |
 Negative | 45 (66.2%) | 96 (64.9%) | 17 (60.7%) | 47 (72.3%) |  |